Lung Reference Set A Application: Dawn Coverley- University of York (2011)
- Abbreviated Name
- Lung Ref Set A App: Coverley (2011)
- Lead Investigator
- Coverley, Dawn — University of York
- Coordinating Investigator
- Feng, Ziding — Fred Hutchinson Cancer Center
- Involved Investigators
Abstract
No abstract availalbe.
Aims
There are four primary clinical questions to be addressed in the pre-validation study: 1) Whether b-variant Ciz1 as a single plasma biomarker has the potential for adding value to current clinical tests (CT scan and/or PET scan) in the diagnostic evaluation of pulmonary nodules with a goal of reducing invasive tests (PET or tissue biopsy) or futile thoracotomies; 2) Whether b-variant Ciz1 as a single plasma biomarker has the potential for adding value to current tests (CT scan and/or PET scan) in the early diagnosis/detection of lung cancer in high risk individuals, with a goal of reducing invasive tests (PET or tissue biopsy) or futile thoracotomies and more importantly, missed cures; and 3) Whether b-variant Ciz1 as a single plasma biomarker has the potential for adding value to current clinical tests (CT scan, PET scan and biopsies) in the staging of lung cancer; and, 4) Whether b-variant Ciz1 as a single plasma biomarker has the potential for adding value to current clinical tests (e.g., CT scan, PET scan and biopsies) in determining prognosis of lung cancer patients; and, A Secondary clinical question is whether b-variant Ciz1 as part of a panel of biomarkers has the potential for adding value to one or more of the above primary clinical utilities.
Analytic Method
Provide adequate detail concerning how statistical analysis of your data generated from the Reference Set(s) samples will be performed and a justification that the requested References Set(s) is/are large enough to demonstrate the utility of the biomarker. Describe the statistical resources at your disposal. If you require statistical support, the EDRN/SPOREs can assist you with this.
Comments
No Data Received at DMCC. Assay didn't work well on the samples provided.
Outcome
A variant of the nuclear matrix factor Ciz1 is prevalent in lung cancer cell lines and tumours, but not in adjacent lung tissue, giving rise to a protein that is stable enough to be detected in just one ul of plasma. This project evaluates the potential of variant Ciz1 as an early detection tool for lung cancer, using variant-selective antibodies.
Publications
- No publications available at this time for this protocol.
Biomarkers
Data Collections
- No data collections available at this time for this protocol.
- Start Date
- Sep 28 2011
- Estimated Finish Date
- Sep 27 2012
- Finish Date
- Mar 27 2012
- Protocol ID
- 341
- Protocol Type
- Reference Set
- Fields of Research
-
- Proteomics
- Collaborative Group
- Lung and Upper Aerodigestive Cancers Research Group
- Cancer Types
-
- Malignant neoplasm of bronchus and lung
- Phased Status
- 1